Recent developments include a significant increase in Q3 2026 revenue, ongoing legal challenges to VOQUEZNA exclusivity, and progress in clinical trial enrollment.

• Phathom Pharmaceuticals reported Q3 2026 net revenues of $84.7 million, representing a 71% increase compared to prior periods [N4][N2].
• The company announced a lawsuit challenging VOQUEZNA exclusivity through May 3, 2032, defending its market position amid FDA public docket establishment and generic drug disputes [N6][N7][N8].
• Phathom completed enrollment in a Phase 2 clinical trial for eosinophilic esophagitis, indicating advancement in its product pipeline [N1].
• The company reaffirmed its fiscal year 2026 outlook following Q3 results [N2].
• Phathom reported a net loss of $13.9 million and EPS of -$0.16 for Q3 2026, reflecting ongoing investment and legal expenses [N5][S2].

Phathom Pharmaceuticals has demonstrated significant revenue growth, with Q3 2026 revenues increasing by 71%. The company’s active defense of VOQUEZNA exclusivity through litigation and regulatory engagement supports its market position. Completion of enrollment in Phase 2 clinical trials for eosinophilic esophagitis indicates progress in pipeline development. The company’s liquidity position, with over $184 million in cash and equivalents and a current ratio above 1.7, provides financial flexibility to support operations and growth initiatives.

Phathom Pharmaceuticals faces risks from ongoing legal challenges to VOQUEZNA exclusivity, which could impact revenue if exclusivity is not maintained. The company reported a net loss in Q3 2026, reflecting ongoing expenses related to litigation, clinical development, and commercialization. Variability in quarterly earnings and the need to defend intellectual property rights may create operational and financial uncertainty. The pharmaceutical market’s regulatory environment and competitive pressures from generic entrants pose additional risks to business stability.

Phathom Pharmaceuticals’ moat is primarily based on its proprietary product VOQUEZNA, which has exclusivity protection currently challenged through legal proceedings. The company’s ability to defend this exclusivity and maintain market share for VOQUEZNA is critical to its competitive position. Additionally, ongoing clinical development programs may contribute to future product pipeline strength. The legal defense of intellectual property rights and regulatory exclusivity forms a significant barrier to generic competition.

• Legal and Regulatory Risks: Phathom is involved in litigation challenging the exclusivity of its VOQUEZNA product, which could affect market exclusivity and revenue streams if the outcome is unfavorable. Regulatory decisions and FDA comments on generic drug challenges add uncertainty.
• Financial Performance Risks: The company reported a net loss in Q3 2026 and has experienced variability in quarterly earnings, indicating ongoing operational costs and investment requirements that may impact profitability.
• Market and Competitive Risks: Phathom operates in a competitive pharmaceutical market with potential generic competition and regulatory hurdles that could affect product sales and market share.

• Phathom Pharmaceuticals, Inc. reported Q3 2026 net revenues of $84.7 million and a net loss of $13.9 million for the quarter ending September 30, 2026.
• The company’s basic and diluted earnings per share for Q3 2026 were both -$0.16 per share.
• As of September 30, 2026, Phathom had cash and cash equivalents of approximately $184.6 million and total current assets of about $308.0 million, with current liabilities of $174.9 million, resulting in a current ratio of 1.76 and a cash ratio of 1.06.
• Phathom Pharmaceuticals is involved in a legal dispute challenging the exclusivity of its product VOQUEZNA, with a lawsuit announced in October 2026 aiming to defend exclusivity through May 3, 2032.
• The company has publicly defended VOQUEZNA’s exclusivity status amid FDA public docket establishment and comments on generic drug challenges.
• Recent news highlights a 71% jump in Q3 revenue and reaffirmation of the fiscal year 2026 outlook by the company.
• Phathom completed enrollment in a Phase 2 clinical trial (PHalcon-EoE-201) for eosinophilic esophagitis as of mid-2026.
• The company reported break-even earnings in Q2 2026 and a loss in Q1 2026, indicating variability in quarterly profitability.
• Phathom Pharmaceuticals has been covered by multiple analysts and financial news outlets, with coverage including earnings call transcripts and legal developments.
• The company’s risk factors include potential adverse impacts from legal proceedings and claims, as noted in its 2026 10-K and 10-Q filings.
• Phathom’s business operations and financials are disclosed in SEC filings including the 10-K filed on February 26, 2026, and the 10-Q filed on October 29, 2026.